title: Dinutuximab: A Novel Immunotherapy in the Treatment of Pediatric Patients With High-Risk Neuroblastoma [Formula: see text].
abstract: Therapy combining dinutuximab with granulocyte macrophage colony stimulating factor, interleukin 2, and isotretinoin has significant side effects; however, these complications are generally predictable and can be managed proactively.
authors.affiliation: 1 Children's Mercy Hospital Kansas City, Kansas City, MI, USA.
authors.forename: Joy
authors.initials: J
authors.lastname: Bartholomew
authors.affiliation: 2 Children's Hospital Los Angeles, Los Angeles, CA, USA.
authors.forename: Tanea
authors.initials: T
authors.lastname: Washington
authors.affiliation: 3 Children's Hospital of Orange County, Los Angeles, CA, USA.
authors.forename: Sharon
authors.initials: S
authors.lastname: Bergeron
authors.affiliation: 4 Primary Children's Hospital, Salt Lake City, UT, USA.
authors.forename: Danelle
authors.initials: D
authors.lastname: Nielson
authors.affiliation: 5 Children's Hospital of Philadelphia, Philadelphia, PA, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Saggio
authors.affiliation: 2 Children's Hospital Los Angeles, Los Angeles, CA, USA.
authors.forename: Lindsay
authors.initials: L
authors.lastname: Quirk
keywords: immunotherapy; infusion management; patient safety